SCREENING CATIONIC LIPIDS FOR GENE DELIVERY ACTIVITY

Information

  • Research Project
  • 2867974
  • ApplicationId
    2867974
  • Core Project Number
    R43CA081803
  • Full Project Number
    1R43CA081803-01
  • Serial Number
    81803
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1999 - 25 years ago
  • Project End Date
    5/31/2000 - 24 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    6/1/1999 - 25 years ago
  • Budget End Date
    5/31/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/1/1999 - 25 years ago

SCREENING CATIONIC LIPIDS FOR GENE DELIVERY ACTIVITY

DESCRIPTION: (adapted from applicant's abstract) ). In order to take full advantage of the clinical gene therapy opportunities offered by synthetic nonviral gene delivery systems, their efficacy needs to be improved, and one way to identify improved synthetic vectors is to screen a large number of candidates in a quantitative, efficacy indicating assay. A high throughput assay which enables 2000 transfection conditions to be quantitatively screened per week is available. From a compound library consisting of 144 pure cationic amphiphiles, 13 compounds were selected at random and 2 compounds were found with gene delivery potency exceeding that of the most potent commercially available cationic lipid reagents. Hence, this library may contain more compounds with equal or even greater potency. The grant will be used to synthesize 10 grams of the most active compound identified so far, and to screen the rest of the lipids in the library. The database from this quantitative survey will be used to develop structure activity relationships to guide the synthesis of more potent cationic lipid analogs and to identify more candidates for commercialization. PROPOSED COMMERCIAL APPLICATION: The cationic lipid formulations identified from this screening activity will be commercialized as tranfection reagents for scientists. Ultimately some of these formulation may become commercialized as human pharmaceutical gene therapy products.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    GENE THERAPY SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES